{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 13,
        "end": 27
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 42,
        "end": 47
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 70,
        "end": 75
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 122,
        "end": 162
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 122,
        "end": 133
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "21418871_10",
  "text": "CONCLUSION : Gastric cancer patients with ERCC1 -118 C/C genotype and XRCC1 -399A / G or A/A genotype may benefit from an oxaliplatin -based adjuvant chemotherapy ."
}
